CT guided 125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma

Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus

“…125 I seed implantation was attempted to treat HCC with PVTT and achieved excellent therapeutic efficacy [15] with a good safety profile [16]. The combination of radiation therapy and TACE has been explored before [17, 18].…”

“…The combination of radiation therapy and TACE has been explored before [17, 18]. Zhang et al [16] evaluated percutaneous puncture 125 I seed implantation combined with TACE for HCC with PVTT under CT-guidance and showed a median survival of 18 months. Wu et al [19] conducted PVS implantation and TACE combined with endovascular implantation of 125 I seeds to treat HCC with PVTT and prolonged the survival of patients and the period of stent patency.…”

Direct Radiofrequency Ablation of Portal Vein Tumor Thrombus in Continuity with Hepatocellular Carcinoma

“…Another direct treatment of PV tumor thrombus is laser ablation, which is reported to have survival rates comparable to those obtained after surgical resection; Lu et al (5) estimated 1-, 2-, and 3-year survival rates of 55.6%, 33.58%, and 22.38%, respectively. CT-guided iodine I 125 implantation seems also to be effective for the treatment of PV tumor thrombus, with a promising response rate as high as 90% reported by Zhang et al (6). Toya et al (7) found that local radiotherapy of portal vein provided a median survival rate up to 9 months and 1-year survival rate up to 39%.…”

Recurrent gliomas

“…Finally, it is also noted that the implantation of low-energy radioactive seeds is able to suppress tumor metastasis by changing the immunophenotype of tumor cells. 16 Given all these advantages, it is of no surprise that high expectations have also been placed on the efficacy of internal implantation to improve the outcome for patients with CNS tumors. However, various studies have shown conflicting results, [17][18][19][20] with some reports of no significant survival advantage.…”